Autologous Stem Cell Transplant: Procedure, Benefits, and Recovery
Updated: 2 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Quick Answer
An autologous stem cell transplant is a cancer treatment in which a patient's own healthy blood stem cells are collected and stored before intensive chemotherapy or radiation. After the high-dose treatment kills cancer cells, the stored cells are returned to restore the bone marrow's ability to make healthy blood cells. [1] It is frequently used for multiple myeloma and certain lymphomas. [1]
What the research says
In real-world data from China, people with newly diagnosed myeloma who had a transplant did better, but they were also younger and healthier. A systematic review of 88 observational studies found a higher complete response rate with ASCT than without (78.5% vs 45.3%), higher 5-year overall survival (70.6% vs 41.3%), and higher 5-year progression-free survival (41.3% vs 18.0%). ASCT recipients were younger (54.5 vs 61.4 years) and had more early-stage disease, so the groups were not directly comparable. Stem cell collection succeeded more often with plerixafor plus G-CSF than with cyclophosphamide plus G-CSF (73.6% vs 49.5%) (PubMed: You et al., Ther Adv Hematol, 2026 [2]).
A second transplant may help people with high-risk myeloma without adding treatment-related deaths. A meta-analysis of 8 randomized trials found that double versus single transplant was linked to better progression-free survival (HR 0.58, 95% CI 0.43–0.80) and overall survival (HR 0.70, 95% CI 0.54–0.90) in patients with at least one unfavorable prognostic marker. Treatment-related mortality was comparable between the two approaches (PubMed: Qin et al., Oncol Lett, 2026 [3]).
For HIV-associated lymphoma, ASCT looks feasible and encouraging, but the data are limited. A meta-analysis of six prospective studies (134 patients) found a pooled six-month non-relapse mortality of 5.39% (95% CI 2.28–9.73%). Among 52 patients with relapsed or refractory disease and survival data, estimated 2-year overall survival was 79.8% (95% CI 68.1–89.3%) and progression-free survival was 77.9% (95% CI 65.9–87.8%). The authors noted that prospective data are limited and comparative data are absent (PubMed: Comelles et al., Cancers, 2026 [4]).
What is an autologous stem cell transplant?
Autologous stem cell transplantation is a critical therapeutic option for individuals facing specific hematologic malignancies. Unlike allogeneic transplants, which use donor cells, the autologous method utilizes the patient's own biological material. This approach eliminates the risk of graft-versus-host disease (GVHD), a common complication in donor-based transplants. The primary goal is to allow the patient to receive much higher, more effective doses of chemotherapy than their bone marrow could otherwise survive.
Conditions Treated
Healthcare providers utilize this procedure for several serious conditions, particularly when standard treatments are insufficient or when cancer returns.
What are the steps of an autologous stem cell transplant?
The journey through an autologous stem cell transplant is complex and occurs in several distinct stages, requiring careful medical supervision at each point.
Preparation and Mobilization
Before the transplant, patients undergo rigorous health screenings, including heart and lung function tests, blood work, and biopsies. A central venous catheter (CVC) is typically placed to facilitate blood draws and infusions. [1] Patients then receive “growth factor” medications to stimulate the bone marrow to produce an excess of stem cells and move them into the bloodstream for collection.
Harvesting (Apheresis)
Once stem cells have moved into the blood, they are collected through a process called apheresis. During this three-to-four-hour procedure, blood is drawn from one arm, passed through a centrifuge machine that filters out the stem cells, and then returned to the patient through the other arm. [1] This collection may be repeated over several days to ensure a sufficient quantity of cells for the transplant.
Conditioning
Conditioning involves receiving high-dose chemotherapy, sometimes combined with radiation therapy, to eliminate cancerous cells throughout the body. [1] This stage usually lasts several days. [1] Because this treatment also destroys healthy bone marrow, patients experience a temporary but significant drop in their blood cell counts.
Infusion and Engraftment
A few days after conditioning, the harvested stem cells are infused back into the patient's body through the CVC. This process is similar to a blood transfusion and takes several hours. [1] The infused cells travel through the bloodstream to the bone marrow, where they begin to grow and produce new blood cells—a process known as engraftment. [1]
What are the benefits and risks of an autologous stem cell transplant?
An autologous stem cell transplant can lead to long-term remission, especially in multiple myeloma, but it also carries substantial risks, most critically life-threatening infection.
Treatment Benefits
For many patients, especially those with multiple myeloma, this procedure can lead to long-term remission, providing years of life without cancer symptoms. [1] It also offers a vital “second chance” for those whose lymphoma has returned after initial treatment or has proven resistant to standard chemotherapy. [1]
Side Effects and Complications
The intensive nature of the conditioning treatment leads to various short-term and long-term side effects.
The most critical immediate risk following the procedure is a life-threatening infection, as the immune system is severely weakened until engraftment is complete. [1]
What does recovery and long-term care after an autologous stem cell transplant involve?
Recovery from a transplant is a gradual process. In the weeks following infusion, patients are closely monitored for signs of infection and to ensure their blood counts are returning to safe levels. Growth factor injections may be used to accelerate the recovery of white blood cells. [1] Long-term follow-up care is essential to monitor for late-onset side effects and to ensure the cancer remains in remission.
Conclusion
Autologous stem cell transplantation remains a cornerstone of treatment for several blood cancers, offering the possibility of extended remission by utilizing the patient's own cellular resources. While the procedure is intensive and carries significant risks, advances in supportive care have made it a safer and more effective option for many. Patients should consult with a hematologist-oncologist to determine if this procedure is the right path for their specific diagnosis and overall health.
Frequently Asked Questions
1. Is an autologous stem cell transplant a cure for cancer?
While it can put cancer into long-term remission—meaning symptoms disappear and tests show no signs of disease—it is not always considered a permanent cure, as cancer can sometimes return. [1]
2. How long does the entire transplant process take?
The entire process, from initial testing and harvesting to recovery after infusion, can take several weeks to a few months, depending on the patient's health and response to treatment.
3. Does the harvesting process hurt?
The apheresis procedure itself is generally painless, though patients must remain still for several hours and may feel slight discomfort from the needles or the central venous catheter.
4. What is the difference between autologous and allogeneic transplants?
An autologous transplant uses your own stem cells, while an allogeneic transplant uses stem cells from a donor, such as a relative or an unrelated volunteer.
5. Can I have a transplant if my cancer has come back?
Yes, autologous transplants are often used specifically for recurrent cancer that has returned after previous treatments were successful.
6. Will I lose my hair during the procedure?
Yes, the high-dose chemotherapy used during the conditioning phase typically causes temporary hair loss.
7. How soon will I know if the transplant worked?
Doctors monitor blood counts daily; the return of white blood cells and platelets (engraftment) usually occurs within two to three weeks, signaling the start of recovery.
8. What are the biggest risks after the infusion?
The most significant immediate risk is infection due to a severely weakened immune system. [1] Long-term risks include infertility and the potential for developing a second, different cancer. [1]
9. Do I need to stay in the hospital for the whole procedure?
Some parts of the process may be done as an outpatient, but the conditioning and infusion stages often require a hospital stay to monitor for side effects and infections.
10. Can autoimmune diseases be treated with this procedure?
Yes, autologous stem cell transplants are sometimes used for severe, treatment-resistant autoimmune diseases, though this is less common than its use in cancer.
11. How do I prepare for an autologous stem cell transplant?
A pre-transplant evaluation checks your overall health, because high-dose chemotherapy can cause significant side effects; tests may include an EKG, echocardiogram, CT scan, complete blood count, liver and kidney blood tests, and a biopsy of the cancer cells [1]. A central venous catheter may be placed in a large chest vein to avoid repeated needle sticks for blood draws and IVs [1]. Once you are cleared, you receive growth factor drugs and other medications to move stem cells from the bone marrow into the bloodstream, and the cells are collected by apheresis over three to four hours, sometimes more than once [1]. Conditioning with high-dose chemotherapy, sometimes with radiation, then follows over several days [1].
12. When should I call my doctor after an autologous stem cell transplant?
Report fever or chills as soon as possible, because infection is the most significant risk until engraftment [1]. Also report shortness of breath, coughing, sneezing or a runny nose, frequent or painful urination, a rash, or lightheadedness or dizziness [1]. Immune recovery can take 3 to 12 months, and the transplant erases your previous vaccine protection [1].
Related Reading
Allogeneic Stem Cell Transplant: Process, Risks and Recovery explains donor stem cell transplants.
References
Cleveland Clinic. What Is an Autologous Stem Cell Transplant? Cleveland Clinic. May 14, 2024. https://my.clevelandclinic.org/health/procedures/autologous-stem-cell-transplant
You J, Zhang Y, Meng Y, et al. Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review. Ther Adv Hematol. 2026;17:20406207261417132. PMID 41685052. https://doi.org/10.1177/20406207261417132
Qin S, Liu Y, Zhang P, et al. Double vs. single autologous stem cell transplantation in patients with multiple myeloma and high-risk factors: A systematic review and meta-analysis. Oncol Lett. 2026;32(2):349. PMID 42368551. https://doi.org/10.3892/ol.2026.15704
Comelles MF, Grudzinski A, Hicks LK. Autologous stem cell transplant for HIV-associated lymphoma: A systematic review and meta-analysis. Cancers (Basel). 2026;18(15):2373. PMID 42588594. https://doi.org/10.3390/cancers18152373
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Comments